Videos

John Leonard, MD, discusses the number of options doctors have to choose from when treating follicular lymphomas.

Differential Diagnosis

Sagar Lonial, MD, discusses an ongoing phase III trial investigating if any interventions would change the natural history of smoldering myeloma.

Christina Baik, MD, MPH, discusses alectinib compared to crizotinib in the first-line setting for patients with ALK-positive lung cancer.

The studies examined ruxolitinib compared to placebo in the United States (COMFORT-I) and best available therapy in Europe (COMFORT-II) for patients with myelofibrosis.

Eytan Stein, MD, discusses the benefits of being able to identify drivers in acute myeloid leukemia and having drugs coming into the clinics to target those biological mutations.

Thomas Stinchcombe, MD, discusses the complicated nature of squamous cell lung cancer. Stinchcombe says that there has been a recent boom in targeted therapies for non-squamous cell lung cancer, though not as much research in squamous cell lung cancer due to its multitude of mutations.

John Leonard, MD, discusses the inefficacy of early treatment and treatment options for patients with follicular lymphoma. Leonard says the relapse rate for patients with follicular lymphoma is around 80%.

Triple Negative Breast Cancer with Andrew Seidman, MD and Joyce O'Shaughnessy, MD

ER+/HER2-Breast Cancer with Adam Brufsky, MD, PhD and Kimberly Blackwell, MD